A cure for the treatment of "Parkinson" disease slows down the development of atrophic side cllerosis

Researchers at the Faculty of Medicine at Tokyo University in Japan have discovered that the medicine can delay the “ribinerol” for the treatment of “Parkinson disease” the development of atrophic lateral sclerosis and delay it on average by about 28 weeks. The atrophic silkserosis is a deadly motor nerve disease that gradually loses control of the muscles, and there is no treatment, and current treatments focus on reducing symptoms and providing supportive care. According to a study published by the “SATM Seal” magazine, some patients responded more to the treatment of “Robinerol” than others, and the researchers managed to predict the clinical response in the laboratory using the motor neurons derived from the stem cells of the patient. Ribinerol is a common remedy in the treatment of Parkinson disease that belongs to a category of medicine known as dopamine. Dopamine increases are a group of medication that mimics the effects of dopamine, which is an important neurotransmitter in the brain. These drugs stimulate dopamine receptors and make similar reactions. Concrete results, and although dopamine is not directly aimed at the treatment of atrophic lateral sclerosis, medication that adapts dopamine or other neurological tankers may be prescribed to manage the specific symptoms associated with the disease. Scientists in previous studies have shown, for example, that it has also been proven to improve motor symptoms in patients with atrophic lateral sclerosis. But the researchers say that the results of “ribinerol” are related to the delay of symptoms for a long time, and it is completely safe. To test the safety and efficacy of the drug in patients with non -family -atrophic lateral sclerosis, the researchers have 20 patients who received care at the University of “Qawa” in Japan. None of the patients qualified the genes to develop the disease, and their average survival was about 20 months. The double blind experience was during the first 24 weeks, which means that patients and doctors do not know which patients received ‘ribiner’ and which of them received a false medicine. After that, for 24 weeks, all patients who want to continue with the “rebel” experiment were given. Many patients withdrew along the road, partly due to the corona pandemic, so that almost half of the patients treated with ‘robiner roll’ and 1/7 were monitored from the imaginary treatment, followed by ‘robiner roll’ for an entire year. No patients withdrew for safety reasons. A safe medicine and to determine whether the drug is effective in delaying the progress of the disease, the team monitored a variety of different measures during the experiment and for a period of four weeks after the end of the treatment. These changes in the physical activity of the patient are reported, the ability to eat and drink independently, and activity data of portable devices, changes that measure the doctor in motion, muscle strength and lung function. “We have found that the drug (robinerol) is safe and acceptable to patients with atrophic lateral sclerosis and shows a treatment promise to help them maintain daily activity and muscle strength,” said the first author of the study, Saturo Morimoto, a neurologist at Kyu University in Tokyo. Patients who received ‘ribinerol’ during the two experiences were physically active as patients in the imaginary medicine group. They also showed slower pace of movements, muscle and lung function and were more likely to survive. The benefits of “ribinerol” compared to the imaginary medicine became clearer as the experiment progressed. Scientists are now planning to perform the third phase of the clinical experiment to emphasize the results and discover the mechanism of the exact medicine in the patients with atrophic side sclerosis. Also read: